Short Interest in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Increases By 378.6%

Key Points

• Pharming Group N.V. experienced a substantial increase in short interest, rising by 378.6% from 1,400 to 6,700 shares between August 15 and August 31.
• A hedge fund, Silverberg Bernstein Capital Management LLC, raised its stake in Pharming Group by 8.6% during the second quarter, owning approximately 0.08% of the company after adding shares.
• Pharming Group reported a profit of $0.06 EPS for the last quarter, exceeding expectations, and generated $93.20 million in revenue compared to analysts' forecasts of $70.36 million.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) saw a significant growth in short interest in August. As of August 31st, there was short interest totaling 6,700 shares, a growth of 378.6% from the August 15th total of 1,400 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 8,000 shares, the short-interest ratio is currently 0.8 days. Based on an average daily trading volume, of 8,000 shares, the short-interest ratio is currently 0.8 days. Currently, 0.0% of the shares of the stock are short sold.

Pharming Group Trading Up 6.0%

PHAR stock traded up $0.83 during midday trading on Wednesday, reaching $14.73. 7,632 shares of the company traded hands, compared to its average volume of 6,869. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.07 and a current ratio of 2.79. The business has a 50 day moving average of $12.23 and a 200-day moving average of $10.45. Pharming Group has a 52-week low of $7.31 and a 52-week high of $17.08. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of -110.62 and a beta of 0.05.

Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.16. Pharming Group had a negative return on equity of 3.31% and a negative net margin of 2.19%.The firm had revenue of $93.20 million for the quarter, compared to the consensus estimate of $70.36 million. Pharming Group has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Pharming Group will post -0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC acquired a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 2,979 shares of the company's stock, valued at approximately $32,000. Institutional investors and hedge funds own 0.03% of the company's stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.